Header Logo

Connection

PADMANEE SHARMA to Neoplasms

Back to Details
This is a "connection" page, showing publications PADMANEE SHARMA has written about Neoplasms.
PADMANEE SHARMA
Connection Strength
2.380
Neoplasms
  1. Loss of ARID1A 'loops' in STING. Trends Immunol. 2024 Aug; 45(8):568-570.
    View in: PubMed
    Score: 0.151
  2. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 04 13; 186(8):1652-1669.
    View in: PubMed
    Score: 0.138
  3. Immune checkpoint therapy: Forging ahead. Sci Transl Med. 2022 11 09; 14(670):eadf2947.
    View in: PubMed
    Score: 0.134
  4. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023 02; 23(2):106-120.
    View in: PubMed
    Score: 0.130
  5. A composite T?cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell. 2022 03 14; 40(3):249-251.
    View in: PubMed
    Score: 0.128
  6. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 04; 11(4):838-857.
    View in: PubMed
    Score: 0.120
  7. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020 02; 20(2):75-76.
    View in: PubMed
    Score: 0.111
  8. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470.
    View in: PubMed
    Score: 0.106
  9. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017 02 09; 168(4):707-723.
    View in: PubMed
    Score: 0.090
  10. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol. 2016 08; 41:23-31.
    View in: PubMed
    Score: 0.086
  11. From the Guest Editor: Immune Checkpoint Therapy as a Weapon Against Cancer. Cancer J. 2016 Mar-Apr; 22(2):67.
    View in: PubMed
    Score: 0.084
  12. Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer J. 2016 Mar-Apr; 22(2):68-72.
    View in: PubMed
    Score: 0.084
  13. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015 Apr 09; 161(2):205-14.
    View in: PubMed
    Score: 0.079
  14. The future of immune checkpoint therapy. Science. 2015 Apr 03; 348(6230):56-61.
    View in: PubMed
    Score: 0.079
  15. Retrospective. Lloyd J. Old (1933-2011). Science. 2012 Jan 06; 335(6064):49.
    View in: PubMed
    Score: 0.063
  16. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy. 2011 Aug; 31(8):813-28.
    View in: PubMed
    Score: 0.061
  17. Cancer immunotherapy: in vivo imaging of adoptively transferred T cells in an immunocompetent host. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):13977-8.
    View in: PubMed
    Score: 0.057
  18. Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines. 2010 Jan; 9(1):89-105.
    View in: PubMed
    Score: 0.055
  19. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009 Mar 15; 15(6):2130-9.
    View in: PubMed
    Score: 0.052
  20. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. J Exp Med. 2024 Oct 07; 221(10).
    View in: PubMed
    Score: 0.038
  21. ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype. J Exp Med. 2024 Apr 01; 221(4).
    View in: PubMed
    Score: 0.037
  22. The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? Eur J Cancer. 2024 Feb; 198:113501.
    View in: PubMed
    Score: 0.036
  23. Neuro-immune interactions and immuno-oncology. Trends Cancer. 2023 08; 9(8):636-649.
    View in: PubMed
    Score: 0.035
  24. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
    View in: PubMed
    Score: 0.032
  25. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. J Immunother Cancer. 2022 01; 10(1).
    View in: PubMed
    Score: 0.032
  26. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3556-3566.
    View in: PubMed
    Score: 0.030
  27. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov. 2021 03; 11(3):614-625.
    View in: PubMed
    Score: 0.029
  28. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251.
    View in: PubMed
    Score: 0.027
  29. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
    View in: PubMed
    Score: 0.024
  30. Genetic biomarker for cancer immunotherapy. Science. 2017 07 28; 357(6349):358.
    View in: PubMed
    Score: 0.023
  31. The Phoenix Rises: The Rebirth of Cancer Immunotherapy. Clin Chem. 2017 07; 63(7):1190-1195.
    View in: PubMed
    Score: 0.023
  32. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35.
    View in: PubMed
    Score: 0.023
  33. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.023
  34. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.021
  35. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980.
    View in: PubMed
    Score: 0.020
  36. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
    View in: PubMed
    Score: 0.019
  37. Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer Immunol Res. 2014 Aug; 2(8):714-9.
    View in: PubMed
    Score: 0.019
  38. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90.
    View in: PubMed
    Score: 0.017
  39. Advances in the development of cancer immunotherapies. Trends Immunol. 2013 Feb; 34(2):90-8.
    View in: PubMed
    Score: 0.017
  40. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214.
    View in: PubMed
    Score: 0.016
  41. The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2. Int J Infect Dis. 2010 Jul; 14(7):e548-52.
    View in: PubMed
    Score: 0.014
  42. Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunol Res. 2024 Aug 01; 12(8):964-987.
    View in: PubMed
    Score: 0.009
  43. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021 10 14; 184(21):5309-5337.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.